Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Ovintiv, Raises Price Target to $65

Citigroup analyst Scott Gruber maintains Ovintiv (NYSE:OVV) with a Buy and raises the price target from $57 to $65.

byBenzinga Newsdesk

September 21, 2022

1 minute read

Citigroup analyst Scott Gruber maintains Ovintiv (NYSE:OVV) with a Buy and raises the price target from $57 to $65.

Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court

By Lara Goldstein

Today, 11:54 PM

Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.

MSSTF

Wells Fargo Maintains Overweight on Rexford Industrial Realty, Raises Price Target to $90

By Benzinga Newsdesk

Today, 11:54 PM

Wells Fargo analyst Blaine Heck maintains Rexford Industrial Realty (NYSE:REXR) with a Overweight and raises the price target from $81 to $90.

REXR

B of A Securities Maintains Buy on First Solar, Raises Price Target to $165

By Benzinga Newsdesk

Today, 11:54 PM

B of A Securities analyst Julien Dumoulin-Smith maintains First Solar (NASDAQ:FSLR) with a Buy and raises the price target from $138 to $165.

FSLR

News

Aethlon Medical Says Due To Lack Of Further Patient Enrollment, Co., UPMC Are In Process Of Terminating Hemopurifier Study At UPMC

By Michael Horton

Today, 11:54 PM

-Reuters

AEMD

Citigroup Maintains Buy on Ovintiv, Raises Price Target to $65

Related Posts

Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court

Wells Fargo Maintains Overweight on Rexford Industrial Realty, Raises Price Target to $90

B of A Securities Maintains Buy on First Solar, Raises Price Target to $165

Aethlon Medical Says Due To Lack Of Further Patient Enrollment, Co., UPMC Are In Process Of Terminating Hemopurifier Study At UPMC